plants; hard to mobilize patients
In contrast to normal allogenic peripheral blood stem cell donors, patients who have received previous chemotherapy and/or radiotherapy before an autotransplant have a 20-25% risk of failing to mobilize sufficient stem cells for a successful autologous stem cell transplant (ASCT). [1] [2] [3] [4] Numerous studies have determined that the minimum stem cell dose needed for rapid hematopoietic engraftment following ASCT is between 1 Â 10 6 and 2.5 Â 10 6 CD34 þ cells/kg. [5] [6] [7] [8] [9] [10] [11] [12] Risk factors for poor mobilization include an underlying diagnosis of lymphoma, [13] [14] [15] multiple myeloma, 15, 16 certain solid tumors, 15 leukemia, 15 bone marrow involvement, 14, [17] [18] [19] prior radiation, 6, 7, 13, 17, 19, 20 increasing number of previous cycles 12, 13, 17, 21 or regimens 4, 14, 19, 22 of chemotherapy, previous stem cell-toxic chemotherapy, 7, [12] [13] [14] 20, 21, [23] [24] [25] [26] previous chemotherapy within 12 months, 18 short time from diagnosis to harvest, 14 disease status, 4 age, 7, 19 bone marrow CD34 þ cell count before mobilization and on apheresis day one, 27 and low WBC 15, 22, 27 or platelet count 27 on the first day of apheresis. Of these, previous stem cell toxic chemotherapy, prior radiation and high number of chemotherapy regimens and/ or cycles appear to be the most significant for poor mobilization.
Whether a patient who fails initial mobilization actually benefits from a second mobilization has not been carefully studied. Initial studies indicated that only those patients with high initial yields can reliably be predicted to achieve a sufficient CD34 þ cell dose. 22, 28, 29 Strategies for remobilization have included the use of chemotherapy plus cytokines, or cytokines alone at standard or escalated doses. 1 Whether or not risk factors for initial mobilization failure can be extended as predictors of poor remobilization has only received minimal attention. Weaver et al 29 identified male gender, diagnosis other than breast cancer, and having obtained 41.5 Â 10 6 CD34 þ cells/kg after first mobilization as risk factors for a poor second mobilization.
Based on a favorable dose response to G-CSF both in normal donors [30] [31] [32] [33] [34] [35] and patients, [36] [37] [38] [39] [40] [41] one consideration is to dose-escalate G-CSF for remobilization (up to 32 mg/ kg). 4, 36, 41 Costs for high-dose G-CSF are significant however. An alternative is the combination of G-CSF þ GM-CSF which may result in the same or perhaps enhanced stem cell yields at lower cost. [42] [43] [44] [45] [46] Winter et al, 42 in fact, found that the addition of G-CSF (5 mg/kg) to GM-CSF (5 mg/kg) on days 7-12 of mobilization resulted in a significant increment in CFU-GM cell yield as compared to G-CSF þ GM-CSF (5 mg/kg each) for all 12 days or G-CSF (5 m/kg) alone. 42 Bashey et al 43 remobilized patients with G-CSF þ GM-CSF (10 mg/kg/day each) who failed an initial mobilization, half of whom achieved the target PBPC dose. Lane et al 44 and Spitzer et al 46 found an equivalent mobilization of CD34 þ cells using the combination G-CSF þ GM-CSF vs G-CSF alone. Madero et al 45 compared the use of G-CSF (12 mg/kg/day) þ GM-CSF (5 mg/kg/day) with G-CSF alone (12 mg/kg/day) for mobilization in children and found that there was no significant difference in CD34 þ cell yield between groups. This alternative to high-dose G-CSF has the potential to substantially reduce the cost of a remobilization procedure.
Over the past 5 years, all patients failing an initial mobilization at our center were remobilized sequentially with either high-dose G-CSF or G-CSF þ GM-CSF. The goals of this retrospective review were to document the success of remobilization and to determine risk factors for a failed second mobilization. In addition, a cost analysis was performed.
Materials and methods

Patient selection
A retrospective chart review was performed for patients undergoing stem cell remobilization who failed to mobilize 2 Â 10 6 CD34 þ cells/kg after their first mobilization at our institution between July 1997 and July 2002. All had to have had a minimum of three aphereses in the first mobilization. We sought to compare the stem cell yields obtained after a second mobilization using either high-dose G-CSF(32 mg/kg/day) or the combination of G-CSF(10 mg/ kg/day) þ GM-CSF(5 mg/kg/day) and to identify risk factors for a failed second mobilization. All patients meeting these requirements seen during that time period were included in this analysis. Patients were excluded if they were donors for allotransplants, underwent only a single mobilization, or received chemotherapy as part of their second mobilization. Treatment history, mobilization history (including daily cell counts, laboratory information and adverse events), transplant preparative regimen, transplant complications and engraftment time were collected. A risk factor analysis was performed considering prior radiation therapy, number of previous chemotherapy regimens, number of previous chemotherapy cycles, number of high risk chemotherapy regimens, chemotherapymobilization interval, cytokines received (G-CSF vs G-CSF þ GM-CSF), first mobilization CD34 þ cell yield, WBC and platelet counts on day 1 of first mobilization, age, sex, weight, diagnosis, disease status and cytokine dose for first mobilization. Chemotherapy regimens were divided into 'high risk' and 'low risk'. 'High risk' standard chemotherapy regimens consisted of agents known to be toxic to the bone marrow: high-dose cytarabine, platinum, procarbazine, fludarabine, nitrosureas, nitrogen mustard and melphalan. In addition, a cost analysis that included cytokine and apheresis costs was undertaken.
Preparative regimens were divided into TBI-based and non-TBI based therapies. Patients with less than 1.0 Â 10 6 stem cells harvested after the first mobilization were defined as 'very poor mobilizers'. Survival analyses excluded patients who did not undergo transplant or did not receive their own stem cells at transplant. Engraftment was defined as the time to recovery of neutrophils 4500/ml and platelets 420 000/ml for a minimum of 7 days. A risk factor analysis of slow engraftment was also performed.
Mobilization procedures
For the initial mobilization, patients mobilized in the early years of this analysis received standard dose G-CSF
Given a high rate of mobilization failure with standard dose cytokines, the last 45 patients received high-dose G-CSF (29-36 mg/kg/day) as their initial mobilization regimen. Rates of failure did not change throughout the time of the analysis.
The second mobilization began a minimum of a week after the first failed mobilization. Patients were sequentially remobilized over the period of the study with either highdose G-CSF(32 mg/kg/day) or the combination of G-CSF-(10 mg/kg/day) þ GM-CSF(5 mg/kg/day). Stem cell collection began on the fifth day of mobilization. All patients underwent at least 3 consecutive days of collection regardless of their stem cell yields. Stem cell yields were calculated daily based on actual body weight. Stem cell doses for transplant included the yields from all mobilization procedures.
Apheresis was done on a COBE Spectra Version 6. Initial mobilization typically processed 10-12 liters of blood; all remobilizations processed 20 liters of blood. Patients who failed a second mobilization were offered a third remobilization at the investigator's discretion and taking into account the patient's disease status.
A cost analysis was performed for patients who underwent remobilization. Center acquisition costs for G-CSF were $245 for 480 mg and $154 for 300 mg vials. Those for GM-CSF were $229 for 500 mg and $115 for 250 mg vials.
Statistical analyses
All statistical analyses were performed using SPSS for Windows (SPSS 10.1, SPSS Inc., Chicago, IL, USA). Descriptive statistics were calculated for all variables. w 2 or Fisher's exact tests were used as appropriate to compare categorical variables with other categorical variables. Mann-Whitney U and Kruskal-Wallis tests were used to compare distributions of continuous/ordinal scaled variables between categorical groups as appropriate. Spearman's rho was used to evaluate associations between continuous/ordinal variables. Univariate and multivariate logistic regression analyses were used to identify predictors of failed second mobilization. A two-sided P-value less than 0.05 was considered statistically significant. Survival was calculated using Kaplan-Meier statistics. This project was reviewed and approved by our local institutional review board.
Results
Patient characteristics
Of the 549 patients undergoing stem cell mobilization for a potential ASCT during the years of the study, 86 met the inclusion criteria for this study (o2. 0 Â 10 6 CD34/kg from the first mobilization procedure) including 47 males (55%) and 39 females (45%). Their median age was 54713.2 (range ¼ 23-73). The underlying diseases and a description of the risk factors by disease are shown in Table 1 . While 67 and 28%, respectively, of the patients seen at our center with the underlying diagnosis of testes cancer and nonHodgkin's lymphoma were poor mobilizers, only 16% of the Hodgkin's disease patients, 7% of patients with breast cancer, 6% of patients with ovarian cancer and 3% of the patients with multiple myeloma were in this category.
Patients requiring remobilization had a significant number of important risk factors previously identified including prior stem cell toxic chemotherapy and/or radiation therapy, more than two previous chemotherapy regimens, and more than 10 previous chemotherapy cycles. The number of poor mobilizers with each risk factor is listed by disease in Table 1 . In all, 76 of the 86 patients (88%) had previously received 'high risk' chemotherapy, 31 (36%) had received prior radiation therapy, 41 (48%) had received more than two previous chemotherapy regimens, and 22 (26%) had received more than 10 previous chemotherapy cycles. In total, 20 patients (23%) had all four of these risk factors, 30 had (35%) three of the four risk factors, 28 patients (33%) had two of the four risk factors and eight patients (9%) had one risk factor. In all, 100% of study patients had at least one poor risk factor with a median of 3 per patient.
Cytokines used for mobilization
Cytokines used for the initial, unsuccessful mobilization in the 86 patients studied were high-dose G-CSF in 52% (n ¼ 45; dose ¼ 29-36 mg/kg/day), standard dose G-CSF in 33% (n ¼ 28; dose ¼ 8-16 mg/kg/day). Five received G-CSF (5 mg/kg/day) þ chemotherapy, seven received the cytokine combination of G-CSF (10-12 mg/kg) þ GM-CSF (5-8 mg/ kg) and one received GM-CSF (5 mg/kg) alone. For the second mobilization, only cytokines were used, with 67 (78%) receiving high-dose G-CSF (16 mg/kg/twice daily) alone and 19 (22%) receiving G-CSF (10 mg/kg/day) þ GM-CSF (5 mg/kg/day) in sequential cohorts. In total, 14 patients failed the second mobilization and were mobilized a third time. Seven received G-CSF (16-37 mg/kg/day), four (5%) received G-CSF (6-10 mg/kg/day) þ chemotherapy, and three (3%) received G-CSF (10-12 mg/kg/day) þ GM-CSF (5-6 mg/kg/day). One patient was mobilized a fourth time using G-CSF þ chemotherapy.
Mobilization results
The 6 /kg72.1 and the median number of days of apheresis was 371.37 (range ¼ 1-7). For those patients who received high-dose G-CSF, the median CD34 þ cell dose/kg was 2.2 Â 10 6 72.0 and the median number of days of apheresis was 371.3. For those who received G-CSF þ GM-CSF, the median CD34 þ cell dose/kg was 1.6 Â 10 6 72.2 and the median number of days of apheresis was 371.1. The CD34 þ cell dose/kg did not differ between the two regimens (P ¼ 0.33). Figure 1 shows the daily mobilization yields for first and second mobilizations.
In total, 23 patients failed a second mobilization defined as a yield after a first and second mobilization of less than 2.0 Â 10 6 CD34 þ cells/kg, 14 of whom were mobilized a In all, 73 patients (85%) of the entire 86 patient cohort achieved the minimum 2.0 Â 10 6 CD34 þ cell/kg threshold after all three mobilizations with a median total CD34 þ cell count of 3.36 Â 10 6 cells/kg72.0. One patient required a fourth mobilization. Of the 86 patients who failed mobilization, 80/86 (93%) went to transplant. Two patients did not receive their own cells due to their negligible CD34 þ cell yields. One received an allotransplant and the other received cord blood. Reasons for failure to undergo transplant were disease progression (n ¼ 3) and too few stem cells (n ¼ 3).
Risk factors for failed second mobilization
Of the 15 risk factors examined (Table 2) , univariate analysis identified three as risk factors for a failed second mobilization. A greater number of previous 'high risk' regimens r ¼ À0.26 (P ¼ 0.015), a shorter time between the last chemotherapy and first mobilization r ¼ 0.25 (P ¼ 0.028), and a higher WBC count on day 1 of first mobilization r ¼ À0.28 (P ¼ 0.04). First mobilization cytokine dose did not affect second mobilization CD34 þ cell dose; however, there was a difference of one apheresis day during the first mobilization between the high and standard dose groups (3 and 4 days, respectively; P ¼ 0.016).
Additional analyses were conducted on the significant risk factors. The number of 'high risk' chemotherapy regimens were categorized into groups of 0-1 and 2-3 and the number of days between last chemotherapy and first mobilization were grouped into p50 and 450 days. Again, both greater number of high-risk regimens and shorter chemotherapy to mobilization interval were identified as risk factors for a poor second mobilization (P ¼ 0.041 and 0.041, respectively). The significant risk factors were then dichotomized into groups of CD34 count p the median (2.24 Â 10 6 /kg) and 4 the median and multivariate logistic regression analyses were performed. A backward stepwise model indicated that there were no independent predictors of second mobilization CD34 þ cell yield.
Of the 58 patients in our study who had less than 1.0 Â 10 6 CD34 cells/kg collected after the initial mobilization, 38 (66%) had X2.0 Â 10 6 CD34 cells/kg after remobilization. After a third mobilization, 47 (81%) met our cutoff criteria for transplant of 2.0 Â 10 6 /kg CD34 þ stem cells.
Cytokine cost analyses for remobilization
For the 67 patients who received G-CSF, the median total cost for the second mobilization was $9016.00 (s.d. ¼ $3814.52; range ¼ $1386-$20 664). For the 19 patients who received G-CSF þ GM-CSF, the median total cost of the second mobilization was $5907.00 (s.d. ¼ $2322.42; range ¼ $2880-$12 532). These were significant at the Po0.0001 level. Both groups received the same median number of days of cytokines (7 days) and number of apheresis days (three aphereses).
Engraftment data and survival
The median time for all transplanted patients to engraft was 11 days for ANC 4500 Â 10 9 /l (s.d. ¼ 3.6. days) and 13 days for platelets 420 000 Â 10 9 /l (s.d. ¼ 6.7 days). Of the 51 patients with less than 1.0 Â 10 6 CD34 þ stem cells collected after the first mobilization, 44 who went on to autotransplant engrafted (86%). Seven of the eight patients who were either not transplanted, or received allogenic marrow or cord blood transplants were in the group of very poor mobilizers and seven of the eight patients who never engrafted after transplant were in this group as well. The median Kaplan-Meier survival time for the 78 patients in our study who received an autotransplant after remobilization was 1294 days (95% CI ¼ 817-1771). The 2-year survival for patients with initial mobilization yields of o1 Â 10 6 CD34 þ cells/kg was 61 vs 58% for patients with 1-2 Â 10 6 CD34 þ cells/kg after initial mobilization.
Discussion
These data indicate that stem cell remobilization after a failed initial mobilization is usually successful at obtaining a CD34 þ cell dose sufficient for transplant (42 Â 10 6 CD34/kg), and that, if necessary, a third mobilization is Remobilization for hard to mobilize patients S Boeve et al often useful. In fact, 93% of our patients who failed an initial mobilization went on to transplant with the majority (90%) achieving rapid hematopoietic engraftment. These results support previously published data; 50 however, they should ideally be confirmed in a randomized prospective trial. Thus for a nonprogressing patient, additional chemotherapy with cytokines just to mobilize CD34 þ stem cells is not warranted. Further, the combination of G-CSF þ GM-CSF at standard doses is equivalent to highdose G-CSF for mobilizing peripheral blood stem cells for the second mobilization, at substantial cost savings. This combination has become the standard of care at our institution.
Previous studies estimated the total cost of using G-CSF for a single standard mobilization to be between $1312 and $2279 for an average of 6.3 days of cytokine usage at 10 mg/ kg/day. [47] [48] [49] The median total cost for high-dose G-CSF in our study was $17 3317$7894 with a maximum cost of $43 120. This large increment is due to the fact that we focused on patients who failed the first mobilization, a subset of 16% (86/552) of the total number of patients mobilized. However, an increment of $17 331 for this 16% is significant and translates to approximately $2800 per patient costs for every autotransplant that would be performed at our center. It is appropriate to consider options to decrease cost.
While there have been a variety of factors associated with a poor first mobilization, our multivariate analysis of risk factors for remobilization identified only one independent factor, that being previous stem cell toxic chemotherapy. Neither prior radiotherapy nor an increasing number of previous chemotherapy regimens or total cycles of chemotherapy predicted poor remobilization in our analysis. We were also unable to confirm Weaver's findings that gender, diagnosis or low initial cell yields were adverse risk fractors. 29 It has been suggested that patients with very low CD34 þ cell yields after the first mobilization attempt are unlikely to achieve a safe bone marrow transplant CD34 cell dose. 22, 28, 29 Of 58 patients in our study who had less than 1.0 Â 10 6 CD34/kg collected after the initial mobilization, 81% met our cutoff criteria for transplant of 2.0 Â 10 6 /kg CD34 þ stem cells after all mobilizations. Of those in this group who underwent an autologous transplant, 86% engrafted. Moreover, the 2-year survival for these very poor mobilizers was similar to those who collected 41 Â 10 6 CD34 þ cells after the first mobilization (61 vs 58%, respectively). These data suggest that given sufficient time for remobilization, the majority of patients will reach sufficient CD34 þ cell yields to proceed to transplant.
Data from Weaver et al 6 and Sugrue et al 22 suggest, in contrast, a poor prognosis for patients with low cell yields after all mobilizations. In all, 54% of Weaver's patients receiving a dose of 1.17-2.48 Â 10 6 CD34 þ cells/kg died within 51-762 days. Similarly, our data show that survival for the 22 patients who received less than 2.5 Â 10 6 CD34 þ cells at transplant was 940 days (95% CI ¼ 0-2065 days), which did not differ statistically from patients who received more than 2.5 Â 10 6 stem cells, who had a median survival of 1440 days, respectively.
Of the patients eventually transplanted, 90% of our study population achieved rapid hematopoietic engraftment reflective of the stem cell doses transplanted. Risk factors for delayed engraftment were noted but were not unique as compared to similar stem cell doses given to patients completing a single mobilization. They included low total CD34 þ cell infusion dose, higher number of prior 'high risk' regimens, radiation-based preparative regimen and higher number of days of previous apheresis.
Whether the G þ GM-CSF combination is superior to high-dose G-CSF alone in preventing high-risk patients from failing an initial mobilization is unknown and is the subject of an ongoing investigation at our institution. If successful at decreasing the number of patients having to be remobilized, the cost savings would be substantial. Future investigations should target other cytokine combinations. In the past, alternatives to remobilization with G-CSF þ GM-CSF have included G-CSF þ SCF, 3, [51] [52] [53] [54] or G-CSF or GM-CSF þ FLT3 ligand, 55, 56 which decrease the percentage of nonmobilizers in heavily pretreated patients. Unfortunately, neither is available in the US for clinical trial use. The combination of thrombopoietin plus G-CSF is currently under investigation 57 and also appears promising in increasing CD34 yields.
